In vitro Assessment of combined polymyxin B and minocycline therapy against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 7, 2017, Pages

  Huang, Dennis ^a   Yu, Brenda ^a   Diep, John K ^a,b   Sharma, Rajnikant ^b   Dudley, Michael ^c   Monteiro, Jussimara ^d   Kaye, Keith S ^e   Pogue, Jason M ^f   Abboud, Cely Saad ^g   Rao, Gauri G ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c Medicines Company   (United States)

^d Clinical Microbiology Section   (Brazil)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

Antimicrobial combinations; Klebsiella pneumoniae; KPC; MDR; Minocycline; Multidrug resistance; Polymyxin

Indexed keywords

MINOCYCLINE; POLYMYXIN B; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEMASE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG POTENTIATION; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYMYXIN B;

EID: 85021693715     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00073-17     Document Type: Article

References (34)

1. Podschun R, Ullmann U. 1998. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 11:589–603.
2. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. 2012. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25:682–707. https://doi.org/10.1128/CMR.05035-11.
3. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29:1099–1106. https://doi.org/10.1086/592412.
4. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. 2008. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 52:1028–1033. https://doi.org/10.1128/AAC.01020-07.
5. Arnold RS, Thom KA, Sharma S, Phillips M, Johnson JK, Morgan DJ. 2011. Emergence of Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. South Med J 104:40–45. https://doi.org/10.1097/SMJ.0b013e3181fd7d5a.
6. Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 53: 60–67. https://doi.org/10.1093/cid/cir202.
7. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. 2013. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:785–796. https://doi.org/10.1016/S1473-3099(13)70190-7.
8. Lee GC, Burgess DS. 2012. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 11:32. https://doi.org/10.1186/ 1476-0711-11-32.
9. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654–663. https://doi.org/10.1128/AAC.01222-13.
10. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, Samonis G, Falagas ME. 2008. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 36:807– 811. https://doi.org/10.1097/CCM.0B013E3181652FAE.
11. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 16:161–168. https://doi.org/10.1016/S1473-3099(15)00424-7.
12. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. 2014. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305–2309. https://doi.org/10.1093/jac/dku168.
13. Zavascki AP, Bulitta JB, Landersdorfer CB. 2013. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 11:1333–1353. https://doi.org/10.1586/14787210.2013.845523.
14. Bishburg E, Shah M, Chan T. 2014. Use of intravenous minocycline for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and resistant Gram-negative organisms: experience in a tertiary care hospital. Infect Dis Clin Pract (Baltim Md) 22:26 –31. https://doi.org/10.1097/IPC.0b013e31828bbb82.
15. Pogue JM, Neelakanta A, Mynatt RP, Sharma S, Lephart P, Kaye KS. 2014. Carbapenem-resistance in Gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis 59:S388–S393. https://doi.org/10.1093/cid/ciu594.
16. Ritchie DJ, Garavaglia-Wilson A. 2014. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis 59:S374–S380. https://doi.org/10.1093/cid/ciu613.
17. Tan TY, Ng LSY, Tan E, Huang G. 2007. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 60:421–423. https://doi.org/10.1093/jac/dkm178.
18. Liang W, Liu XF, Huang J, Zhu DM, Li J, Zhang J. 2011. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis 11:109. https://doi.org/10.1186/1471-2334-11-1.
19. Rodríguez CH, Nastro M, Vay C, Famiglietti A. 2015. In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates. J Med Microbiol 64:1196–1200. https://doi.org/10.1099/jmm.0.000147.
20. Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH. 2015. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother 59:2720 –2725. https://doi.org/10.1128/AAC.04110-14.
21. Zhang Y, Chen F, Sun E, Ma R, Qu C, Ma L. 2013. In vitro antibacterial activity of combinations of fosfomycin, minocycline and polymyxin B on pan-drug-resistant Acinetobacter baumannii. Exp Ther Med 5:1737–1739.
22. Yang Y-S, Lee Y, Tseng K-C, Huang W-C, Chuang M-F, Kuo S-C, Yang Lauderdale T-L, Chen T-L. 25 April 2016. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother https://doi.org/10.1128/aac.02994-15.
23. Barth N, Ribeiro VB, Zavascki AP. 2015. In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials. Antimicrob Agents Chemother 59:3596–3597. https://doi.org/10.1128/AAC.00365-15.
24. Chopra I, Roberts M. 2001. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232–260. https://doi.org/10.1128/MMBR.65.2.232-260.2001.
25. Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Turkoglu S, Nordmann P. 2015. The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae. J Antimicrob Chemother 70:75–80. https://doi.org/10.1093/jac/dku323.
26. Diep J, Jacobs DM, Sharma R, Covelli J, Bowers DR, Russo TA, Rao GG. 21 November 2016. Polymyxin B in combination with rifampin and meropenem against polymyxin B-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother https://doi.org/10.1128/aac.02121-16.
27. Abboud CS, Monteiro J, Stryjewski ME, Zandonadi EC, Barbosa V, Dantas D, Sousa EE, Fonseca MJ, Jacobs DM, Pignatari AC, Kiffer C, Rao GG. 2016. Post-surgical mediastinitis due to carbapenem-resistant Enterobacteriaceae: clinical, epidemiological and survival characteristics. Int J Antimicrob Agents 47:386–390. https://doi.org/10.1016/j.ijantimicag.2016.02.015.
28. CLSI. 2016. Performance standards for antimicrobial susceptibility testing, 26th ed. CLSI supplement M100S. Clinical and Laboratory Standards Institute, Wayne, PA.
29. Monteiro J, Widen RH, Pignatari AC, Kubasek C, Silbert S. 2012. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 67:906–909. https://doi.org/10.1093/jac/dkr563.
30. Aminov RI, Chee-Sanford JC, Garrigues N, Teferedegne B, Krapac IJ, White BA, Mackie RI. 2002. Development, validation, and application of PCR primers for detection of tetracycline efflux genes of Gram-negative bacteria. Appl Environ Microbiol 68:1786–1793. https://doi.org/10.1128/AEM.68.4.1786-1793.2002.
31. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256 –265. https://doi.org/10.1093/jac/dkl224.
32. Saivin S, Houin G. 1988. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 15:355–366. https://doi.org/10.2165/00003088-198815060-00001.
33. Bishburg E, Bishburg K. 2009. Minocycline – an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents 34: 395–401. https://doi.org/10.1016/j.ijantimicag.2009.06.021.
34. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524–531. https://doi.org/10.1093/cid/cit334.